EPCAM and hepatocellular carcinoma: Especially in the context of liver regeneration we found a highly increased expression of a number of LPC/BEC markers when NTBC therapy was discontinued of which some, including Epcam, could also play a key role in hepatocellular carcinoma development associated with HT1 disease progression.